CXCR2 and neoplasm: Since RAS is a crucial signaling pathway known to regulate the homeostatic proliferation of normal cells, it was important for us to evaluate if the CXCR2 antagonists provide a selective growth disadvantage to mutant KRAS-bearing tumor cells versus normal cells [29].